Patents Assigned to B.M.R.A. Corporation B.V.
-
Publication number: 20080113973Abstract: The invention is directed to methods and compositions that can be used in the treatment of inflammation, pain and cardiovascular disorders. Methods and compositions are described involving the combination of a thromboxane A2 receptor antagonist and an inhibitor specific for cyclooxygenase-2.Type: ApplicationFiled: November 2, 2007Publication date: May 15, 2008Applicant: B.M.R.A. Corporation B.V.Inventor: Hans Brunner
-
Patent number: 6905456Abstract: A device for intermittent compression of human extremities such as, for instance, the region of the calves, to assist the return of body fluid in the direction of the heart. The device comprises a cuff and a pressure generator, which intermittently pressurizes the cuff, the cuff comprising in the direction of return a width of maximally 25 centimeters. The device further comprises a pressure generator that can be secured directly to the cuff or secured to the body or to clothing. This highly compact, handy configuration enables mobile application of the device in every-day situations to assist physical well-being.Type: GrantFiled: June 25, 1999Date of Patent: June 14, 2005Assignee: B.M.R.A. Corporation B.V.Inventors: Hans R. Brunner, Daniel Hayoz, Beat Steffen, Ueli Haueter, Andreas Schaer
-
Patent number: 6709651Abstract: The present invention is directed to methods of treating a wide variety of diseases, disorders and conditions characterized by excessive activity of substance P. The treatment involves administering peptidases that recognize and selectively cleave polypeptides at Xaa-Pro sequences.Type: GrantFiled: July 3, 2001Date of Patent: March 23, 2004Assignee: B.M.R.A. Corporation B.V.Inventors: Eric Grouzmann, Jean-Silvain Lacroix, Michel Monod
-
Publication number: 20040009905Abstract: The present invention is directed to agonists of neuropeptide Y (NPY) or PYY that are formed by combining these peptides or a portion of these peptides with a template that promotes biologically active folds. Typically, templates consist of cyclized peptides containing one or more naphthyl ring structures. The agonists may be used in the treatment of diseases and conditions known to be responsive to NPY or PYY and, particularly in the treatment of asthma, rhinitis, and bronchitis.Type: ApplicationFiled: June 18, 2003Publication date: January 15, 2004Applicant: B.M.R.A. Corporation B.V.Inventors: Manfred Mutter, Jean-Silvain Lacroix, Eric Grouzmann
-
Publication number: 20030165489Abstract: The present invention is directed to methods of treating mucosal inflammation associated with rhinitis or sinusitis by administering peptidases that recognize and cleave polypeptides at Xaa-Pro sequences. In addition, the invention encompasses therapeutic packages in which pharmaceutical compositions containing the peptidases are preloaded in a device suitable for intranasally delivering drug.Type: ApplicationFiled: November 27, 2001Publication date: September 4, 2003Applicant: B.M.R.A. Corporation B.V.Inventors: Eric Grouzmann, Jean-Silvain Lacroix, Michel Monod
-
Patent number: 6337069Abstract: The present invention is directed to methods of treating mucosal inflammation associated with rhinitis or sinusitis by administering peptidases that recognize and cleave polypeptides at Xaa-Pro sequences. In addition, the invention encompasses therapeutic packages in which pharmaceutical compositions containing the peptidases are preloaded in a device suitable for intranasally delivering drug.Type: GrantFiled: February 28, 2001Date of Patent: January 8, 2002Assignee: B.M.R.A. Corporation B.V.Inventors: Eric Grouzmann, Jean-Silvain Lacroix, Michel Monod
-
Patent number: 6017879Abstract: The present invention is directed to agonists of neuropeptide Y (NPY) or PYY that are formed by combining these peptides or a portion of these peptides with a template that promotes biologically active folds. Typically, templates consist of cyclized peptides containing one or more naphthyl ring structures. The agonists may be used in the treatment of diseases and conditions known to be responsive to NPY or PYY and, particularly in the treatment of asthma, rhinitis, and bronchitis.Type: GrantFiled: April 3, 1998Date of Patent: January 25, 2000Assignee: B.M.R.A. Corporation B.V.Inventors: Manfred Mutter, Jean-Silvain Lacroix, Eric Grouzmann
-
Patent number: 5817912Abstract: The present invention is directed to transgenic animals which have been engineered by homologous recombination to be deficient in the expression of the neuropeptide Y Y1 receptor. The invention encompasses the DNA constructs and engineered embryonic stem cells used to produce the animals, the transgenic animals themselves, and assays which utilize either the animals or tissues derived from the animals.Type: GrantFiled: January 16, 1997Date of Patent: October 6, 1998Assignee: B.M.R.A. Corporation B.V.Inventors: Thierry Pedrazzini, Hans R. Brunner
-
Patent number: 5635359Abstract: The activity of angiotensin converting enzyme (ACE) is measured in biological samples as body fluids. ACE-activity is estimated in minimally diluted specimens, using the natural substrate angiotensin I at close to physiological concentration. Femtomoles of generated angiotensin II are trapped by specific high affinity monoclonal antibodies and thus protected from degradation by angiotensinases during the incubation step. The same antibodies are subsequently used for quantitation by radioimmunoassay.Type: GrantFiled: July 5, 1994Date of Patent: June 3, 1997Assignee: B.M.R.A. Corporation B.V.Inventors: Hans R. Brunner, Jurg Nussberger
-
Patent number: 5407803Abstract: The activity of angiotensin converting enzyme (ACE) is measured in biological samples as body fluids. ACE-activity is estimated in minimally diluted specimens, using the natural substrate angiotensin I at close to physiological concentration. Femtomoles of generated angiotensin II are trapped by specific high affinity monoclonal antibodies and thus protected from degradation by angiotensinases during the incubation step. The same antibodies are subsequently used for quantitation by radioimmunoassay.Type: GrantFiled: January 31, 1992Date of Patent: April 18, 1995Assignee: B.M.R.A. Corporation B.V.Inventors: Hans R. Brunner, Juerg Nussberger